Payment overview · 2025
General Payments
$201.22
11 reported records · 5 companies
Healthcare provider profile · identity verified
Christopher Lee Granger, MD
Allopathic & Osteopathic Physicians|Family Medicine · DERIDDER, LA · NPI 1861472110
Verified facts
What the public records show
CMS Open Payments records show Christopher Lee Granger, MD received $201.22 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 66.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $133.16 | 66.2% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.11 | 10.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.23 | 8.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.08 | 7.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.64 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $201.22 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.74 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.27 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.27 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 237 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
206 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
101 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
237 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 940 | 177 |
| Pantoprazole Sodium | Pantoprazole Sodium | 835 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 765 | 157 |
| Gabapentin | Gabapentin | 707 | 142 |
| Losartan Potassium | Losartan Potassium | 588 | 140 |
| Prednisone | Prednisone | 507 | 226 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 483 | 133 |
| Metformin Hcl | Metformin Hcl | 455 | 113 |
| Eliquis | Apixaban | 429 | 51 |
| Potassium Chloride | Potassium Chloride | 426 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 402 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 400 | 113 |
| Sertraline Hcl | Sertraline Hcl | 390 | 84 |
| Alprazolam | Alprazolam | 375 | 69 |
| Lisinopril | Lisinopril | 354 | 82 |
| Omeprazole | Omeprazole | 353 | 88 |
| Furosemide | Furosemide | 348 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 335 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 326 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 308 | 90 |
| Donepezil Hcl | Donepezil Hcl | 305 | 44 |
| Trazodone Hcl | Trazodone Hcl | 293 | 64 |
| Tramadol Hcl | Tramadol Hcl | 289 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 270 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 61 |
| Memantine Hcl | Memantine Hcl | 245 | 25 |
| Ozempic | Semaglutide | 237 | 44 |
| Carvedilol | Carvedilol | 232 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 224 | 61 |
| Azithromycin | Azithromycin | 219 | 159 |
| Allopurinol | Allopurinol | 211 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 36 |
| Jardiance | Empagliflozin | 206 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 44 |
| Mirtazapine | Mirtazapine | 176 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 61 |
| Meloxicam | Meloxicam | 150 | 56 |
| Simvastatin | Simvastatin | 148 | 35 |
| Montelukast Sodium | Montelukast Sodium | 140 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 140 | 31 |
| Finasteride | Finasteride | 138 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 41 |
| Glipizide | Glipizide | 124 | 30 |
| Celecoxib | Celecoxib | 122 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 36 |
| Ezetimibe | Ezetimibe | 116 | 35 |
| Mupirocin | Mupirocin | 116 | 58 |
| Januvia | Sitagliptin Phosphate | 115 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 115 | 11 |
| Glimepiride | Glimepiride | 114 | 33 |
| Torsemide | Torsemide | 114 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 45 |
| Divalproex Sodium | Divalproex Sodium | 107 | 11 |
| Atenolol | Atenolol | 104 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 17 |
| Trulicity | Dulaglutide | 101 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 96 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 96 | 19 |
| Levetiracetam | Levetiracetam | 91 | 12 |
| Levofloxacin | Levofloxacin | 90 | 64 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 56 |
| Bupropion Xl | Bupropion Hcl | 86 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 85 | 66 |
| Clonazepam | Clonazepam | 84 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | suppressed |
| Aripiprazole | Aripiprazole | 83 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 27 |
| Lorazepam | Lorazepam | 83 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 82 | 72 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 82 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | suppressed |
| Pregabalin | Pregabalin | 82 | 20 |
| Famotidine | Famotidine | 81 | 17 |
| Buspirone Hcl | Buspirone Hcl | 76 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 21 |
| Methocarbamol | Methocarbamol | 75 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | 19 |
| Fluconazole | Fluconazole | 73 | 46 |
| Labetalol Hcl | Labetalol Hcl | 73 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 73 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 73 | 23 |
| Ondansetron Odt | Ondansetron | 72 | 38 |
| Primidone | Primidone | 69 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 17 |
| Risperidone | Risperidone | 66 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 17 |
| Ingrezza | Valbenazine Tosylate | 63 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 19 |
| Mounjaro | Tirzepatide | 60 | 16 |
| Sucralfate | Sucralfate | 60 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 23 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 59 | 11 |
| Methylprednisolone | Methylprednisolone | 59 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 17 |
| Nystatin | Nystatin | 58 | 39 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Lovastatin | Lovastatin | 55 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 20 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 52 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 15 |
| Cefuroxime | Cefuroxime Axetil | 50 | 42 |
| Cephalexin | Cephalexin | 50 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 22 |
| Synthroid | Levothyroxine Sodium | 50 | suppressed |
| Glipizide Er | Glipizide | 49 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 11 |
| Spironolactone | Spironolactone | 48 | suppressed |
| Topiramate | Topiramate | 48 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 47 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 39 |
| Meclizine Hcl | Meclizine Hcl | 46 | 15 |
| Nifedipine Er | Nifedipine | 46 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 45 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 12 |
| Hydrocortisone | Hydrocortisone | 43 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 16 |
| Megestrol Acetate | Megestrol Acetate | 40 | 13 |
| Amoxicillin | Amoxicillin | 39 | 32 |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 31 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 15 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Temazepam | Temazepam | 35 | 15 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 16 |
| Linzess | Linaclotide | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 14 |
| Digoxin | Digoxin | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Metronidazole | Metronidazole | 29 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 25 |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 22 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | 11 |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 11 |
| Naproxen | Naproxen | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 17 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Budesonide Dr | Budesonide | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 13 |
| Procrit | Epoetin Alfa | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Sulfasalazine | Sulfasalazine | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Novolog | Insulin Aspart | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $201.22 · 11 records | Novo Nordisk Inc | Cologuard Collection Kit, FANAPT, MOUNJARO, Ozempic, REXULTI, Rybelsus, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error